To compare the anti-tumor efficiencies of mFMC63-CAR2 T cells, mFMC63-CAR3 T cells, and mFMC63-CAR4 T cells, an in vitro killing assay against CD19+ target cells was conducted. This evidence concerns the gene CD19 and neoplasm.